|
|
D-mannose |
|
Vaxjo ID |
218 |
|
Vaccine Adjuvant Name |
D-mannose |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
D-mannose is described as a hexose sugar and functions as a transgene adjuvant to improve spinal non-viral IL-10 gene delivery. |
|
Stage of Development |
Research |
|
Components |
D-mannose as a transgene adjuvant to control chronic neuropathic pain |
|
Structure |
It is a hexose sugar. |
|
Preparation |
The paper describes its use in pretreatment and co-injection, but not its preparation itself |
|
Function |
Peri-spinal treatment with D-mannose may optimize naked pDNA-IL-10 transgene uptake for suppression of allodynia, and is a novel approach to tune spinal immune cells toward pro-phagocytic phenotype for improved non-viral gene therapy |
| Related Vaccine(s) |
|
| References |
Dengler et al., 2014: Dengler EC, Alberti LA, Bowman BN, Kerwin AA, Wilkerson JL, Moezzi DR, Limanovich E, Wallace JA, Milligan ED. Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain. Journal of neuroinflammation. 2014; 11; 92. [PubMed: 24884664].
|
|
